Results 51 to 60 of about 13,106 (183)

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

British Journal of Haematology, EarlyView.
In FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty‐two per cent of patients treated with intention‐to‐transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain
Wei Yee Chan, Hannah Al‐Yousuf, Ho Pui Jeff Lam, Sarah Leong, Jiexin Zheng, Richard Burt, Andrew J. Wilson, Ke Xu, Kate Stringaris, Samah Alimam, Kavita Raj, Rajeev Gupta, Panagiotis Kottaridis, Anish Tailor, Rebecca Burgoyne, Marc R. Mansour, Asim Khwaja, Rob Sellar, Elspeth M. Payne, Jenny O'Nions   +19 more
wiley   +1 more source

Socioeconomic inequality in treatment of acute myeloid leukaemia (AML) in England, 2015–2022: A population‐based study

British Journal of Haematology, EarlyView.
Summary The socioeconomic inequality in acute myeloid leukaemia (AML) survival may be driven by differential access to intensive chemotherapy (ICT). We aimed to quantify socioeconomic inequality in the receipt of ICT among patients with AML in England and identify its key drivers. We evaluated 10 495 patients with de novo AML identified in the national
Koki Shimizu, Mari Kajiwara Saito, Camille Maringe, Yasushi Miyazaki, Bernard Rachet   +4 more
wiley   +1 more source

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.

PLoS ONE, 2020
Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten ...
Pierre Bories, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, Véronique De Mas, Thomas Filleron, Manon Cassou, Audrey Sarry, Luc-Matthieu Fornecker, Célestine Simand, Sarah Bertoli, Christian Recher, Eric Delabesse   +15 more
doaj   +1 more source

The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases

Frontiers in Pharmacology
BackgroundAzacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation to reverse epigenetic modifications and restore normal ...
Zhaorui Wang, Linlin Guo, Youfu He, Baiquan Zhang, Yang Wang, Juan Ding   +5 more
doaj   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source

Successful allo‐hematopoietic stem cell transplantation using washed hematopoietic stem cells in a pediatric patient complicated by acute myeloid leukemia and severe anaphylaxis to blood product

Pediatric Investigation, EarlyView.
Jieyu Tian, Guanghua Zhu, Maoquan Qin, Chenguang Jia, Shuxuan Ma, Bin Wang, Yanhui Luo   +6 more
wiley   +1 more source

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia

Haematologica
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechanism.
Guru Subramanian Guru Murthy, Antoine N. Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hinman, Sonia Maldonado-Schmidt, Annapoorna Venkatachalam, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Mark Litzow, Scott H. Kaufmann, Ehab Atallah   +17 more
doaj   +1 more source

Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment

European Journal of Haematology, EarlyView.
ABSTRACT Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low‐dose cytarabine, hydroxyurea, or supportive care, with
Antonella Bruzzese, Enrica Antonia Martino, Santino Caserta, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source